SCHEMBL4106010

SCHEMBL4106010

CC(=O)c1cccc(NC(=O)Nc2cccc(OC(F)F)c2)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.63
KMT2A Q03164 4/20 0.63
NPC1 O15118 4/20 0.58
RAB9A P51151 4/20 0.58
MITF O75030 1/20 0.58
ALDH1A1 P00352 6/20 0.58
KDM4E B2RXH2 1/20 0.58
CYP1A2 P05177 1/20 0.56
MAPT P10636 6/20 0.56
POLB P06746 1/20 0.56
GFER P55789 1/20 0.56
HTT P42858 3/20 0.55
CA12 O43570 1/20 0.55
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
CA9 Q16790 1/20 0.55
LMNA P02545 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
EPHX2 P34913 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4112123 0.92 ALDH1A1 (0.63) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL4117865 0.92 MAPT (0.67) MEN1KMT2ANPC1RAB9AMITF
SCHEMBL4106286 0.89 MAPT (0.65) MEN1KMT2ANPC1RAB9AMITF
SCHEMBL4112022 0.89 RAB9A (0.61) MEN1KMT2ANPC1RAB9AMITF
SCHEMBL4104707 0.87 KMT2A (0.65) MEN1KMT2ANPC1RAB9AMITF
SCHEMBL4112724 0.85 TP53 (0.70) MEN1KMT2ANPC1RAB9AMITF
SCHEMBL4118632 0.85 MAPT (0.64) MEN1KMT2ANPC1RAB9AMITF
SCHEMBL2277217 0.85 KMT2A (0.54) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL4117383 0.84 RAB9A (0.67) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL4113233 0.84 KMT2A (0.65) MEN1KMT2ANPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US claimed
EP-1804785-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2007-07-11 EP claimed
WO-2006049941-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2006-05-11 WO claimed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 MEN1 3273/4885KMT2A 2807/4885NPC1 927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.